Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

When Cambridge, Mass.-based QurAlis Corporation officially launched two years ago, the company had a goal of developing therapies for three different forms of Amyotrophic Lateral Sclerosis (ALS).